Hepatitis A virus (HAV) strain HAV/HFS/GBM was adapted to and grown in human diploid fibroblast cells. The HAV was concentrated by ammonium sulphate precipitation and high-speed centrifugation. The virus was inactivated by beta-propiolacton and purified by sedimentation through a 20% solution of suc
Molecular analysis of antigenicity and immunogenicity of a vaccine-induced escape mutant of hepatitis B virus
β Scribed by Toru Shizuma; Kiyoshi Hasegawa; Kayo Ishikawa; Takuma Naritomi; Aiko Iizuka; Naoko Kanai; Miho Ogawa; Nobuyuki Torii; Riho Joh; Naoaki Hayashi
- Publisher
- Springer Japan
- Year
- 2003
- Tongue
- English
- Weight
- 360 KB
- Volume
- 38
- Category
- Article
- ISSN
- 0944-1174
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
A hepatitis B vaccine produced in yeast by recombinant DNA technology was evaluated using 5-micrograms and 10-micrograms doses in a randomized trial lasting 7 months in 110 male armed forces recruits aged 17-19 years. Results were compared to those of an identical trial of a plasma-derived vaccine.
The successful prevention of infection with hepatitis B virus (HBV) has been achieved by vaccination with purified hepatitis B surface antigen (HBsAg). The ability of a novel synthetic HBV envelope antigen vaccine (Hep B-3, Hepa-geneβ’; Medeva), which contains part of the pre-S1 and the complete pre-
HBsAg is the most important serological marker for acute or chronic hepatitis B. Nevertheless, there are reports of HBsAg-negative virus carriers, either with anti-HBc as the only marker for hepatitis B virus (HBV) infection or even positive for anti-HBs and anti-HBc. We report isolates from a patie